China's BGI Genomics, Chinese life science investor Healthlink Capital and global innovation fund Future Planet Capital have invested an undisclosed amount of capital in Congenica, a U.K. clinical genomics software developer for inherited diseases.
The new capital injection comes two months after Congenica raised US$10 million in a series B financing round from existing investors, Cambridge Innovation Capital and Amadeus Capital Partners, and new investor Parkwalk Advisors in February.
Alongside the investment, BGI Genomics and UniteGen, Healthlink’s associated clinical diagnostic lab, have signed commercial contracts to use Congenica’s proprietary enterprise software to support their operations in China.
These contracts represent Congenica’s first commercialization in the territory and are consistent with Congenica’s interna...
This news article comes via , who is the copyright owner of this information and news. FintekAsia.com has licensed the rights to this article and any republication or re-distribution in whole or in part of this content is strictly prohibited without the express consent of China Money Network
